Tirzepatide 10 mg

Client Peptide Bros · LY3298176 · C225H348N48O68

VERIFIED ID **NP-B7RTIR-T10**

Sample as received

CLIENT
Peptide Bros

SAMPLE REFERENCE
NPA-26-09102

CLIENT LOT
PB-TIRZ-10-2609

DATE RECEIVED
10 Sep 2026

DATE ANALYSED
16 Sep 2026

DATE ISSUED
17 Sep 2026

Scan QR to verify

HPLC PURITY (AREA %)

99.59%

RP-HPLC-UV 214 nm · single dominant peak

IDENTITY (ESI-MS)

Confirmed

Theory 4813.45 Da
Found 4813.52 Da
Δ = 0.07 Da

NET CONTENT

10.62 mg

Appearance: white lyophilized cake
Endotoxin: not requested

COLUMN / METHOD
C18 4.6 × 250 mm, 5 µm · H2O/MeCN + 0.1% TFA

MAIN PEAK RT
9.56 min

ANALYST
A. Chen, M.Sc.

REVIEWER
R. Singh, Ph.D.

LABORATORY
Vancouver, BC

Statement

The results above describe the sample as received under the sample reference on this certificate. They do not certify any other vial, lot, or subsequent handling. HPLC purity is chromatographic area percent and is not net peptide content. Identity is intact-mass agreement with the theoretical mass of the named sequence.

Electronically issued. Verify at the URL encoded in the QR code. Printed copies are uncontrolled.
NorthPeak Analytical Ltd. does not manufacture or sell peptides.

Chromatogram and peak table

RP-HPLC-UV 214 nm · Sample NPA-26-09102 · NP-B7RTIR-T10



Integrated peaks

#	RT (min)	Area %	Assignment
1	8.88	0.22	Related impurity
2	**9.56**	**99.59**	**Tirzepatide (main peak)**
3	10.28	0.30	Related impurity

Method notes

Mobile phase A: water + 0.1% TFA. Mobile phase B: acetonitrile + 0.1% TFA.
Gradient: 5–65% B over 12 min, 1.0 mL/min, column 30 °C, injection 10 µL.
Purity = (main peak area / sum of integrated peak areas) × 100.
Salts, counter-ions and residual water are not quantified by UV and are not reported as HPLC impurities.
Mass confirmation by positive-mode ESI. Acceptance: observed mass within ±0.5 Da of theory for this peptide class.